Related Experiment Videos
[131I]metaiodobenzylguanidine treatment of a malignant paraganglioma
J L Baulieu1, D Guilloteau, G Calais
1Service de Médecine Nucléaire, Hôpital Bretonneau, Tours, France.
Journal of Nuclear Biology and Medicine (Turin, Italy : 1991)
|October 1, 1991
Abstract:
The bone metastases of a malignant, non-secreting paraganglioma were treated with [131I]metaiodobenzylguanidine (131I-MIBG) over a 10-year period. Initial treatment (131I-MIBG: 9.6 GBq) resulted in a decrease in the number of bone metastases from 16 to 2. At three years, a relapse with primary tumor regrowth and liver metastasis was again treated with 131I-MIBG (22.2 GBq). A decrease in the number of bone metastases and MIBG uptake was again observed.